VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Brookfield Infrastructure Partners L.P. vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Brookfield Infrastructure Partners L.P.
BIP · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Brookfield Infrastructure Partners L.P.'s moat claims, evidence, and risks.
View BIP analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: Brookfield Infrastructure Partners L.P. leads (74 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Brookfield Infrastructure Partners L.P. has 4 segments; Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Primary market structure: Quasi-Monopoly vs Oligopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: Brookfield Infrastructure Partners L.P. has 4 moat types across 3 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
Brookfield Infrastructure Partners L.P.
Utilities
Regulated and contracted utility infrastructure (electric transmission, gas pipelines/distribution, metering and residential energy services)
Global
Regulators and contracted counterparties; residential and commercial end-users via utility networks
Owner-operator of regulated networks and contracted utility assets
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Brookfield Infrastructure Partners L.P. strengths
Bristol-Myers Squibb Company strengths
Segment mix
Brookfield Infrastructure Partners L.P. segments
Full profile >Utilities
Quasi-Monopoly
Transport
Oligopoly
Midstream
Oligopoly
Data
Oligopoly
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.